Immunic, Inc. (IMUX) 10-Year Financial Performance & Capital Metrics

IMUX • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutImmunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.Show more

Revenue $0
EBITDA -$98M +1.2%
Net Income -$101M -7.4%
EPS (Diluted) -1.00 +52.6%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -424.44% -223.3%
ROIC -
Debt/Equity 0.05 +18.2%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 14 (bottom 14%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-6.34%

EPS CAGR

10Y-

5Y-

3Y-

TTM30.08%

ROCE

10Y Avg-120.26%

5Y Avg-150.24%

3Y Avg-214.17%

Latest-406.32%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	6.32K	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-1%	-	-	-	-	-	-	-
Cost of Goods Sold+	1.33M	1.81M	998K	15K	50K	0	0	0	0	0
COGS % of Revenue	-	286.3%	-	-	-	-	-	-	-	-
Gross Profit+	-1.33M	-1.8M	-998K	-15K	-50K	0	0	0	0	0
Gross Margin %	-	-285.3%	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-0.36%	0.45%	0.98%	-2.33%	1%	-	-	-	-
Operating Expenses+	52.12M	41.27M	52.66M	38.41M	37.03M	48.97M	91.67M	119.49M	99.22M	98.05M
OpEx % of Revenue	-	6534.48%	-	-	-	-	-	-	-	-
Selling, General & Admin	12.35M	11.22M	13.31M	13.59M	14.52M	10.33M	13.3M	15.26M	16.01M	18.01M
SG&A % of Revenue	-	1776.69%	-	-	-	-	-	-	-	-
Research & Development	39.77M	30.05M	39.34M	24.82M	22.51M	38.64M	61.12M	71.25M	83.22M	80.05M
R&D % of Revenue	-	4757.79%	-	-	-	-	-	-	-	-
Other Operating Expenses	97K	297K	0	28K	0	0	17.25M	32.97M	0	0
Operating Income+	-52.12M	-41.27M	-52.66M	-42.02M	-37.03M	-48.97M	-91.67M	-119.49M	-99.22M	-98.05M
Operating Margin %	-	-6534.48%	-	-	-	-	-	-	-	-
Operating Income Growth %	-0.04%	0.21%	-0.28%	0.2%	0.12%	-0.32%	-0.87%	-0.3%	0.17%	0.01%
EBITDA+	-50.79M	-39.46M	-51.66M	-42.01M	-36.98M	-48.93M	-91.58M	-119.41M	-99.11M	-97.92M
EBITDA Margin %	-	-6248.18%	-	-	-	-	-	-	-	-
EBITDA Growth %	-0.03%	0.22%	-0.31%	0.19%	0.12%	-0.32%	-0.87%	-0.3%	0.17%	0.01%
D&A (Non-Cash Add-back)	1.33M	1.81M	998K	15K	50K	39K	85K	77K	111K	134K
EBIT	-52.02M	-40.97M	-52.08M	-15.15M	-37.03M	-48.97M	-91.67M	-86.52M	-99.22M	-98.05M
Net Interest Income+	0	0	0	0	0	58K	66K	0	3.08M	3.39M
Interest Income	58K	284K	650K	521K	107K	58K	66K	1.04M	3.08M	3.39M
Interest Expense	0	0	0	0	107K	0	0	1.04M	0	0
Other Income/Expense	97K	297K	577K	455K	2.1M	4.95M	-1.28M	-919K	5.61M	-2.46M
Pretax Income+	-52.02M	-40.97M	-52.08M	-41.48M	-34.93M	-44.02M	-92.94M	-120.41M	-93.61M	-100.51M
Pretax Margin %	-	-6487.45%	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	549K	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-52.02M	-40.97M	-52.08M	-41.48M	-34.83M	-44.02M	-92.94M	-120.41M	-93.61M	-100.51M
Net Margin %	-	-6487.45%	-	-	-	-	-	-	-	-
Net Income Growth %	-0.09%	0.21%	-0.27%	0.2%	0.16%	-0.26%	-1.11%	-0.3%	0.22%	-0.07%
Net Income (Continuing)	-52.02M	-40.97M	-52.08M	-11.54M	-34.93M	-44.02M	-92.94M	-120.41M	-93.61M	-100.51M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-82.73	-52.21	-52.26	-39.16	-4.51	-2.81	-3.92	-3.78	-2.11	-1.00
EPS Growth %	-0.03%	0.37%	-0%	0.25%	0.88%	0.38%	-0.4%	0.04%	0.44%	0.53%
EPS (Basic)	-82.73	-52.21	-52.26	-39.16	-4.51	-2.81	-3.92	-3.78	-2.11	-1.00
Diluted Shares Outstanding	628.82K	784.69K	996.48K	1.06M	7.72M	15.66M	23.65M	31.82M	44.32M	100.17M
Basic Shares Outstanding	628.82K	784.69K	996.48K	1.06M	7.72M	15.66M	23.65M	31.82M	44.32M	100.17M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	85.09M	61.46M	58.12M	14.23M	32.23M	133.75M	104.99M	125.86M	52.53M	39.33M
Cash & Short-Term Investments	83.42M	59.99M	56.9M	13.32M	29.37M	127.45M	86.86M	116.37M	46.67M	35.67M
Cash Only	83.42M	59.99M	56.9M	13.32M	29.37M	127.45M	86.86M	106.75M	46.67M	35.67M
Short-Term Investments	0	0	0	0	0	0	0	9.63M	0	0
Accounts Receivable	0	0	0	0	408K	295K	2.15M	296K	703K	684K
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	-191K	-408K	0	0	5.61M	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	533K	1.47M	1.22M	0	1.55M	1.35M	1.12M	3.59M	2.84M	1.11M
Total Non-Current Assets+	3.99M	2.56M	2.26M	746K	33.73M	34.12M	34.11M	1.89M	1.76M	1.54M
Property, Plant & Equipment	3.81M	2.5M	2.15M	709K	713K	1.1M	1.1M	1.85M	1.76M	1.54M
Fixed Asset Turnover	-	0.00x	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	32.97M	32.97M	32.97M	0	0	0
Intangible Assets	0	3.09M	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	184K	-3.03M	108K	37K	42K	42K	42K	43K	0	0
Total Assets+	89.08M	64.03M	60.38M	14.98M	65.95M	167.86M	139.1M	127.75M	54.3M	40.87M
Asset Turnover	-	0.00x	-	-	-	-	-	-	-	-
Asset Growth %	-0.18%	-0.28%	-0.06%	-0.75%	3.4%	1.55%	-0.17%	-0.08%	-0.57%	-0.25%
Total Current Liabilities+	6.66M	5.48M	10.28M	2.51M	7.07M	8.4M	11.4M	13.08M	24.73M	22.18M
Accounts Payable	1.22M	780K	1.05M	268K	2.42M	3.7M	3.5M	4.28M	5.1M	7.85M
Days Payables Outstanding	335.59	157.47	383.65	6.52K	17.69K	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	1000K	0	0	0	0	0
Other Current Liabilities	3.27M	2.55M	5.64M	564K	343K	82K	851K	7.33M	17.48M	676K
Current Ratio	12.79x	11.22x	5.65x	5.67x	4.56x	15.93x	9.21x	9.62x	2.12x	1.77x
Quick Ratio	12.79x	11.22x	5.65x	5.75x	4.62x	15.93x	9.21x	9.20x	2.12x	1.77x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	101K	100K	59K	41K	520K	679K	584K	992K	639K	264K
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	520K	679K	584K	992K	639K	264K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	101K	100K	59K	41K	0	0	0	0	0	0
Total Liabilities	6.76M	5.58M	10.34M	2.55M	7.59M	9.08M	11.98M	14.07M	25.37M	22.44M
Total Debt+	0	0	0	37.19M	520K	976K	992K	1.56M	1.33M	1M
Net Debt	-83.42M	-59.99M	-56.9M	23.87M	-28.85M	-126.48M	-85.87M	-105.18M	-45.34M	-34.66M
Debt / Equity	-	-	-	2.99x	0.01x	0.01x	0.01x	0.01x	0.05x	0.05x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-346.09x	-	-	-114.78x	-	-
Total Equity+	82.33M	58.45M	50.04M	12.43M	58.36M	158.78M	127.11M	113.68M	28.93M	18.43M
Equity Growth %	-0.16%	-0.29%	-0.14%	-0.75%	3.7%	1.72%	-0.2%	-0.11%	-0.75%	-0.36%
Book Value per Share	130.92	74.48	50.22	11.73	7.56	10.14	5.37	3.57	0.65	0.18
Total Shareholders' Equity	82.33M	58.45M	50.04M	12.43M	58.36M	158.78M	127.11M	113.68M	28.93M	18.43M
Common Stock	3K	3K	4K	4K	1K	2K	3K	4K	4K	8K
Retained Earnings	-202.86M	-243.82M	-295.95M	-337.43M	-59.91M	-103.93M	-196.87M	-317.28M	-410.89M	-511.4M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	80K	83K	78K	80K	-1.37M	-4.11M	-252K	3.04M	3.76M	4.21M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-49.95M	-35.77M	-40.4M	-43.16M	-28.55M	-46.12M	-83.23M	-65.14M	-70.83M	-84.77M
Operating CF Margin %	-	-5664.82%	-	-	-	-	-	-	-	-
Operating CF Growth %	-0.22%	0.28%	-0.13%	-0.07%	0.34%	-0.62%	-0.8%	0.22%	-0.09%	-0.2%
Net Income	-52.02M	-40.97M	-52.08M	-41.48M	-34.93M	-44.02M	-92.94M	-120.41M	-93.61M	-100.51M
Depreciation & Amortization	1.33M	1.81M	998K	727K	50K	39K	85K	77K	111K	134K
Stock-Based Compensation	4.03M	4.68M	5.48M	3.74M	6.51M	2.75M	5.95M	7.93M	7.1M	8.53M
Deferred Taxes	0	0	0	1.22M	-355K	0	4.33M	0	0	0
Other Non-Cash Items	6.68M	85K	255K	234K	1.54M	-2.53M	8.63M	37.73M	523K	6.52M
Working Capital Changes	-3.29M	-1.38M	4.95M	-7.61M	-1.36M	-2.37M	-9.28M	9.53M	15.05M	564K
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	281K	-459K	287K	-770K	-462K	1M	176K	799K	817K	3.15M
Cash from Investing+	-1.28M	-21K	-678K	-415K	10.54M	-146K	-67K	-9.74M	9.46M	-264K
Capital Expenditures	-2.34M	-556K	-685K	-597K	-55K	-146K	-67K	-112K	-334K	-264K
CapEx % of Revenue	-	88.04%	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	1.06M	535K	7K	182K	-75K	0	0	0	0	0
Cash from Financing+	32.42M	12.37M	37.98M	4K	34.9M	144.43M	42.84M	95.76M	1.03M	74.54M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	232K	19K	-14K	4K	-270K	0	92K	187K	180K	77K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-52.29M	-36.33M	-41.08M	-43.76M	-28.6M	-46.27M	-83.3M	-65.26M	-71.16M	-85.03M
FCF Margin %	-	-5752.86%	-	-	-	-	-	-	-	-
FCF Growth %	-0.24%	0.31%	-0.13%	-0.07%	0.35%	-0.62%	-0.8%	0.22%	-0.09%	-0.19%
FCF per Share	-83.16	-46.30	-41.23	-41.31	-3.70	-2.95	-3.52	-2.05	-1.61	-0.85
FCF Conversion (FCF/Net Income)	0.96x	0.87x	0.78x	1.04x	0.82x	1.05x	0.90x	0.54x	0.76x	0.84x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-57.84%	-58.21%	-96.01%	-132.78%	-98.39%	-40.54%	-65.02%	-100.01%	-131.28%	-424.44%
Return on Invested Capital (ROIC)	-	-	-	-214.13%	-84.41%	-118.82%	-186.94%	-360.29%	-	-
Gross Margin	-	-28529.7%	-	-	-	-	-	-	-	-
Net Margin	-	-648744.6%	-	-	-	-	-	-	-	-
Debt / Equity	-	-	-	2.99x	0.01x	0.01x	0.01x	0.01x	0.05x	0.05x
Interest Coverage	-	-	-	-	-346.09x	-	-	-114.78x	-	-
FCF Conversion	0.96x	0.87x	0.78x	1.04x	0.82x	1.05x	0.90x	0.54x	0.76x	0.84x
Revenue Growth	-	-	-100%	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Immunic, Inc. (IMUX) grew revenue by 0.0% over the past year. Growth has been modest.

Immunic, Inc. (IMUX) reported a net loss of $103.0M for fiscal year 2024.

Dividend & Returns

Immunic, Inc. (IMUX) has a return on equity (ROE) of -424.4%. Negative ROE indicates the company is unprofitable.

Immunic, Inc. (IMUX) had negative free cash flow of $89.6M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Immunic, Inc. (IMUX) 10-Year Financial Performance & Capital Metrics

IMUX • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

Revenue $0
EBITDA -$98M +1.2%
Net Income -$101M -7.4%
EPS (Diluted) -1.00 +52.6%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -424.44% -223.3%
ROIC -
Debt/Equity 0.05 +18.2%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 14 (bottom 14%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-6.34%

EPS CAGR

10Y-

5Y-

3Y-

TTM30.08%

ROCE

10Y Avg-120.26%

5Y Avg-150.24%

3Y Avg-214.17%

Latest-406.32%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	6.32K	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-1%	-	-	-	-	-	-	-
Cost of Goods Sold+	1.33M	1.81M	998K	15K	50K	0	0	0	0	0
COGS % of Revenue	-	286.3%	-	-	-	-	-	-	-	-
Gross Profit+	-1.33M	-1.8M	-998K	-15K	-50K	0	0	0	0	0
Gross Margin %	-	-285.3%	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-0.36%	0.45%	0.98%	-2.33%	1%	-	-	-	-
Operating Expenses+	52.12M	41.27M	52.66M	38.41M	37.03M	48.97M	91.67M	119.49M	99.22M	98.05M
OpEx % of Revenue	-	6534.48%	-	-	-	-	-	-	-	-
Selling, General & Admin	12.35M	11.22M	13.31M	13.59M	14.52M	10.33M	13.3M	15.26M	16.01M	18.01M
SG&A % of Revenue	-	1776.69%	-	-	-	-	-	-	-	-
Research & Development	39.77M	30.05M	39.34M	24.82M	22.51M	38.64M	61.12M	71.25M	83.22M	80.05M
R&D % of Revenue	-	4757.79%	-	-	-	-	-	-	-	-
Other Operating Expenses	97K	297K	0	28K	0	0	17.25M	32.97M	0	0
Operating Income+	-52.12M	-41.27M	-52.66M	-42.02M	-37.03M	-48.97M	-91.67M	-119.49M	-99.22M	-98.05M
Operating Margin %	-	-6534.48%	-	-	-	-	-	-	-	-
Operating Income Growth %	-0.04%	0.21%	-0.28%	0.2%	0.12%	-0.32%	-0.87%	-0.3%	0.17%	0.01%
EBITDA+	-50.79M	-39.46M	-51.66M	-42.01M	-36.98M	-48.93M	-91.58M	-119.41M	-99.11M	-97.92M
EBITDA Margin %	-	-6248.18%	-	-	-	-	-	-	-	-
EBITDA Growth %	-0.03%	0.22%	-0.31%	0.19%	0.12%	-0.32%	-0.87%	-0.3%	0.17%	0.01%
D&A (Non-Cash Add-back)	1.33M	1.81M	998K	15K	50K	39K	85K	77K	111K	134K
EBIT	-52.02M	-40.97M	-52.08M	-15.15M	-37.03M	-48.97M	-91.67M	-86.52M	-99.22M	-98.05M
Net Interest Income+	0	0	0	0	0	58K	66K	0	3.08M	3.39M
Interest Income	58K	284K	650K	521K	107K	58K	66K	1.04M	3.08M	3.39M
Interest Expense	0	0	0	0	107K	0	0	1.04M	0	0
Other Income/Expense	97K	297K	577K	455K	2.1M	4.95M	-1.28M	-919K	5.61M	-2.46M
Pretax Income+	-52.02M	-40.97M	-52.08M	-41.48M	-34.93M	-44.02M	-92.94M	-120.41M	-93.61M	-100.51M
Pretax Margin %	-	-6487.45%	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	549K	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-52.02M	-40.97M	-52.08M	-41.48M	-34.83M	-44.02M	-92.94M	-120.41M	-93.61M	-100.51M
Net Margin %	-	-6487.45%	-	-	-	-	-	-	-	-
Net Income Growth %	-0.09%	0.21%	-0.27%	0.2%	0.16%	-0.26%	-1.11%	-0.3%	0.22%	-0.07%
Net Income (Continuing)	-52.02M	-40.97M	-52.08M	-11.54M	-34.93M	-44.02M	-92.94M	-120.41M	-93.61M	-100.51M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-82.73	-52.21	-52.26	-39.16	-4.51	-2.81	-3.92	-3.78	-2.11	-1.00
EPS Growth %	-0.03%	0.37%	-0%	0.25%	0.88%	0.38%	-0.4%	0.04%	0.44%	0.53%
EPS (Basic)	-82.73	-52.21	-52.26	-39.16	-4.51	-2.81	-3.92	-3.78	-2.11	-1.00
Diluted Shares Outstanding	628.82K	784.69K	996.48K	1.06M	7.72M	15.66M	23.65M	31.82M	44.32M	100.17M
Basic Shares Outstanding	628.82K	784.69K	996.48K	1.06M	7.72M	15.66M	23.65M	31.82M	44.32M	100.17M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	85.09M	61.46M	58.12M	14.23M	32.23M	133.75M	104.99M	125.86M	52.53M	39.33M
Cash & Short-Term Investments	83.42M	59.99M	56.9M	13.32M	29.37M	127.45M	86.86M	116.37M	46.67M	35.67M
Cash Only	83.42M	59.99M	56.9M	13.32M	29.37M	127.45M	86.86M	106.75M	46.67M	35.67M
Short-Term Investments	0	0	0	0	0	0	0	9.63M	0	0
Accounts Receivable	0	0	0	0	408K	295K	2.15M	296K	703K	684K
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	-191K	-408K	0	0	5.61M	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	533K	1.47M	1.22M	0	1.55M	1.35M	1.12M	3.59M	2.84M	1.11M
Total Non-Current Assets+	3.99M	2.56M	2.26M	746K	33.73M	34.12M	34.11M	1.89M	1.76M	1.54M
Property, Plant & Equipment	3.81M	2.5M	2.15M	709K	713K	1.1M	1.1M	1.85M	1.76M	1.54M
Fixed Asset Turnover	-	0.00x	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	32.97M	32.97M	32.97M	0	0	0
Intangible Assets	0	3.09M	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	184K	-3.03M	108K	37K	42K	42K	42K	43K	0	0
Total Assets+	89.08M	64.03M	60.38M	14.98M	65.95M	167.86M	139.1M	127.75M	54.3M	40.87M
Asset Turnover	-	0.00x	-	-	-	-	-	-	-	-
Asset Growth %	-0.18%	-0.28%	-0.06%	-0.75%	3.4%	1.55%	-0.17%	-0.08%	-0.57%	-0.25%
Total Current Liabilities+	6.66M	5.48M	10.28M	2.51M	7.07M	8.4M	11.4M	13.08M	24.73M	22.18M
Accounts Payable	1.22M	780K	1.05M	268K	2.42M	3.7M	3.5M	4.28M	5.1M	7.85M
Days Payables Outstanding	335.59	157.47	383.65	6.52K	17.69K	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	1000K	0	0	0	0	0
Other Current Liabilities	3.27M	2.55M	5.64M	564K	343K	82K	851K	7.33M	17.48M	676K
Current Ratio	12.79x	11.22x	5.65x	5.67x	4.56x	15.93x	9.21x	9.62x	2.12x	1.77x
Quick Ratio	12.79x	11.22x	5.65x	5.75x	4.62x	15.93x	9.21x	9.20x	2.12x	1.77x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	101K	100K	59K	41K	520K	679K	584K	992K	639K	264K
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	520K	679K	584K	992K	639K	264K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	101K	100K	59K	41K	0	0	0	0	0	0
Total Liabilities	6.76M	5.58M	10.34M	2.55M	7.59M	9.08M	11.98M	14.07M	25.37M	22.44M
Total Debt+	0	0	0	37.19M	520K	976K	992K	1.56M	1.33M	1M
Net Debt	-83.42M	-59.99M	-56.9M	23.87M	-28.85M	-126.48M	-85.87M	-105.18M	-45.34M	-34.66M
Debt / Equity	-	-	-	2.99x	0.01x	0.01x	0.01x	0.01x	0.05x	0.05x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-346.09x	-	-	-114.78x	-	-
Total Equity+	82.33M	58.45M	50.04M	12.43M	58.36M	158.78M	127.11M	113.68M	28.93M	18.43M
Equity Growth %	-0.16%	-0.29%	-0.14%	-0.75%	3.7%	1.72%	-0.2%	-0.11%	-0.75%	-0.36%
Book Value per Share	130.92	74.48	50.22	11.73	7.56	10.14	5.37	3.57	0.65	0.18
Total Shareholders' Equity	82.33M	58.45M	50.04M	12.43M	58.36M	158.78M	127.11M	113.68M	28.93M	18.43M
Common Stock	3K	3K	4K	4K	1K	2K	3K	4K	4K	8K
Retained Earnings	-202.86M	-243.82M	-295.95M	-337.43M	-59.91M	-103.93M	-196.87M	-317.28M	-410.89M	-511.4M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	80K	83K	78K	80K	-1.37M	-4.11M	-252K	3.04M	3.76M	4.21M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-49.95M	-35.77M	-40.4M	-43.16M	-28.55M	-46.12M	-83.23M	-65.14M	-70.83M	-84.77M
Operating CF Margin %	-	-5664.82%	-	-	-	-	-	-	-	-
Operating CF Growth %	-0.22%	0.28%	-0.13%	-0.07%	0.34%	-0.62%	-0.8%	0.22%	-0.09%	-0.2%
Net Income	-52.02M	-40.97M	-52.08M	-41.48M	-34.93M	-44.02M	-92.94M	-120.41M	-93.61M	-100.51M
Depreciation & Amortization	1.33M	1.81M	998K	727K	50K	39K	85K	77K	111K	134K
Stock-Based Compensation	4.03M	4.68M	5.48M	3.74M	6.51M	2.75M	5.95M	7.93M	7.1M	8.53M
Deferred Taxes	0	0	0	1.22M	-355K	0	4.33M	0	0	0
Other Non-Cash Items	6.68M	85K	255K	234K	1.54M	-2.53M	8.63M	37.73M	523K	6.52M
Working Capital Changes	-3.29M	-1.38M	4.95M	-7.61M	-1.36M	-2.37M	-9.28M	9.53M	15.05M	564K
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	281K	-459K	287K	-770K	-462K	1M	176K	799K	817K	3.15M
Cash from Investing+	-1.28M	-21K	-678K	-415K	10.54M	-146K	-67K	-9.74M	9.46M	-264K
Capital Expenditures	-2.34M	-556K	-685K	-597K	-55K	-146K	-67K	-112K	-334K	-264K
CapEx % of Revenue	-	88.04%	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	1.06M	535K	7K	182K	-75K	0	0	0	0	0
Cash from Financing+	32.42M	12.37M	37.98M	4K	34.9M	144.43M	42.84M	95.76M	1.03M	74.54M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	232K	19K	-14K	4K	-270K	0	92K	187K	180K	77K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-52.29M	-36.33M	-41.08M	-43.76M	-28.6M	-46.27M	-83.3M	-65.26M	-71.16M	-85.03M
FCF Margin %	-	-5752.86%	-	-	-	-	-	-	-	-
FCF Growth %	-0.24%	0.31%	-0.13%	-0.07%	0.35%	-0.62%	-0.8%	0.22%	-0.09%	-0.19%
FCF per Share	-83.16	-46.30	-41.23	-41.31	-3.70	-2.95	-3.52	-2.05	-1.61	-0.85
FCF Conversion (FCF/Net Income)	0.96x	0.87x	0.78x	1.04x	0.82x	1.05x	0.90x	0.54x	0.76x	0.84x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-57.84%	-58.21%	-96.01%	-132.78%	-98.39%	-40.54%	-65.02%	-100.01%	-131.28%	-424.44%
Return on Invested Capital (ROIC)	-	-	-	-214.13%	-84.41%	-118.82%	-186.94%	-360.29%	-	-
Gross Margin	-	-28529.7%	-	-	-	-	-	-	-	-
Net Margin	-	-648744.6%	-	-	-	-	-	-	-	-
Debt / Equity	-	-	-	2.99x	0.01x	0.01x	0.01x	0.01x	0.05x	0.05x
Interest Coverage	-	-	-	-	-346.09x	-	-	-114.78x	-	-
FCF Conversion	0.96x	0.87x	0.78x	1.04x	0.82x	1.05x	0.90x	0.54x	0.76x	0.84x
Revenue Growth	-	-	-100%	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Immunic, Inc. (IMUX) grew revenue by 0.0% over the past year. Growth has been modest.

Immunic, Inc. (IMUX) reported a net loss of $103.0M for fiscal year 2024.

Dividend & Returns

Immunic, Inc. (IMUX) has a return on equity (ROE) of -424.4%. Negative ROE indicates the company is unprofitable.

Immunic, Inc. (IMUX) had negative free cash flow of $89.6M in fiscal year 2024, likely due to heavy capital investments.